Pharmaceuticals - Germany

Germany

Germany's Pharmaceuticals market is expected to achieve a revenue of €36.84bn by 2024.
Among the various markets, Oncology Drugs are anticipated to hold the largest share with a projected market volume of €7.26bn in the same year.
With an annual growth rate (CAGR 2024-2028) of 6.68%, the revenue is predicted to increase, resulting in a market volume of €47.71bn by 2028.
When comparing globally, United States is expected to generate the highest revenue, amounting to €590.60bn in 2024.
Germany's pharmaceutical market is dominated by a strong emphasis on research and development, leading to innovative drug discoveries and advancements in the healthcare industry.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The Pharmaceuticals market in Germany has been experiencing significant growth in the past few years.

Customer preferences: Customers in Germany have been showing an increased interest in natural and herbal medicines, resulting in a rise in demand for alternative therapies and supplements. This trend is driven by a growing awareness of the potential side effects of traditional pharmaceuticals and a desire for more natural remedies. Additionally, there is a growing demand for personalized medicine, which tailors treatments to an individual's genetic makeup.

Trends in the market: One of the major trends in the pharmaceutical market in Germany is the increasing focus on digitalization. This includes the use of electronic prescriptions, telemedicine, and digital health apps. This trend is driven by the need for more efficient and cost-effective healthcare services, as well as the growing availability of digital technologies. Another trend is the shift towards biosimilars, which are lower-cost alternatives to biologic drugs. This trend is driven by the need to reduce healthcare costs and improve access to treatments.

Local special circumstances: Germany has a strong healthcare system, with universal coverage and a high level of public spending on healthcare. This has created a favorable environment for pharmaceutical companies, as there is a large market for their products. Additionally, Germany has a strong research and development sector, with many universities and research institutes focused on the life sciences.

Underlying macroeconomic factors: The German economy has been performing well in recent years, with steady GDP growth and low unemployment. This has led to increased consumer spending on healthcare, including pharmaceuticals. Additionally, Germany has a large aging population, which is driving demand for healthcare services and products. However, there are also challenges facing the pharmaceutical market in Germany, including increasing competition from generic drugs and pressure to reduce healthcare costs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.